ES2592402T3 - Radioinmunoconjugados y usos de los mismos - Google Patents

Radioinmunoconjugados y usos de los mismos Download PDF

Info

Publication number
ES2592402T3
ES2592402T3 ES13195682.3T ES13195682T ES2592402T3 ES 2592402 T3 ES2592402 T3 ES 2592402T3 ES 13195682 T ES13195682 T ES 13195682T ES 2592402 T3 ES2592402 T3 ES 2592402T3
Authority
ES
Spain
Prior art keywords
antibody
cells
identity
sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13195682.3T
Other languages
English (en)
Spanish (es)
Inventor
Roy H. Larsen
Jostein Dahle
Øyvind S. Bruland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thor Medical ASA
Original Assignee
Nordic Nanovector AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nordic Nanovector AS filed Critical Nordic Nanovector AS
Application granted granted Critical
Publication of ES2592402T3 publication Critical patent/ES2592402T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES13195682.3T 2010-01-29 2011-01-28 Radioinmunoconjugados y usos de los mismos Active ES2592402T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
NO20100143 2010-01-29
US299524P 2010-01-29

Publications (1)

Publication Number Publication Date
ES2592402T3 true ES2592402T3 (es) 2016-11-30

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13195682.3T Active ES2592402T3 (es) 2010-01-29 2011-01-28 Radioinmunoconjugados y usos de los mismos
ES11700972.0T Active ES2469140T3 (es) 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES11700972.0T Active ES2469140T3 (es) 2010-01-29 2011-01-28 Nuevos radioinmunoconjugados y usos de los mismos

Country Status (25)

Country Link
US (2) US8628749B2 (https=)
EP (2) EP2705857B1 (https=)
JP (2) JP5646652B2 (https=)
KR (2) KR101758409B1 (https=)
CN (2) CN104338154B (https=)
AU (1) AU2011209441B2 (https=)
BR (1) BR112012018843B8 (https=)
CA (1) CA2786655C (https=)
DK (2) DK2528627T3 (https=)
ES (2) ES2592402T3 (https=)
HR (1) HRP20140538T1 (https=)
IL (2) IL221091A (https=)
MX (2) MX342539B (https=)
NO (1) NO331080B1 (https=)
NZ (1) NZ601055A (https=)
PH (2) PH12012501516A1 (https=)
PL (1) PL2528627T3 (https=)
PT (1) PT2528627E (https=)
RS (1) RS53346B (https=)
RU (2) RU2560587C9 (https=)
SG (1) SG182685A1 (https=)
SI (1) SI2528627T1 (https=)
UA (1) UA108631C2 (https=)
WO (1) WO2011092295A2 (https=)
ZA (1) ZA201205007B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014014258A2 (pt) * 2011-12-13 2020-10-27 Nordic Nanovector As. molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b
HK1202156A1 (en) * 2012-03-30 2015-09-18 Immunogen, Inc. Methods for increasing efficacy of cd37-based therapy
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
BR112015030457A2 (pt) * 2013-06-07 2017-08-22 Nordic Nanovector As Método para regular positivamente a expressão de antígeno
JP6510518B2 (ja) 2013-08-01 2019-05-08 アジェンシス，インコーポレイテッド Ｃｄ３７タンパク質に結合する抗体薬物結合体（ａｄｃ）
CA2980462C (en) * 2015-04-07 2023-08-01 The Curators Of The University Of Missouri Nanoparticle immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
SG11201901672RA (en) * 2016-09-16 2019-03-28 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
CN111372613A (zh) * 2017-11-22 2020-07-03 诺帝克纳诺维科特公司 放射免疫缀合物与其他药物联合治疗非霍奇金淋巴瘤
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
US20220211885A1 (en) * 2019-04-25 2022-07-07 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN117241832A (zh) * 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
JP2006511532A (ja) * 2002-12-13 2006-04-06 ミトラ、メディカル、テクノロジー、アクチボラグ 三官能性試薬によって連結された、エフェクター機能および親和性機能を有する抗リンパ腫ターゲティング剤
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CN1767860A (zh) * 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
HRP20140338T1 (hr) * 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
PE20140196A1 (es) * 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37

Also Published As

Publication number Publication date
JP5646652B2 (ja) 2014-12-24
KR20170084349A (ko) 2017-07-19
PT2528627E (pt) 2014-06-12
NO331080B1 (no) 2011-09-26
NO20100143A1 (no) 2011-08-01
CN102762230A (zh) 2012-10-31
CN102762230B (zh) 2014-08-13
BR112012018843B1 (pt) 2020-09-24
US20140147384A1 (en) 2014-05-29
CN104338154B (zh) 2017-09-22
UA108631C2 (xx) 2015-05-25
MX2012008695A (es) 2012-11-23
KR20130028051A (ko) 2013-03-18
IL221091A (en) 2015-03-31
BR112012018843A2 (pt) 2017-10-17
CA2786655A1 (en) 2011-08-04
EP2705857A3 (en) 2014-07-30
PH12012501516A1 (en) 2024-04-03
JP2013518086A (ja) 2013-05-20
PL2528627T3 (pl) 2014-08-29
HK1179157A1 (en) 2013-09-27
WO2011092295A2 (en) 2011-08-04
AU2011209441B2 (en) 2016-03-03
EP2705857A2 (en) 2014-03-12
HK1195736A1 (en) 2014-11-21
MX342539B (es) 2016-10-04
WO2011092295A3 (en) 2011-11-24
DK2528627T3 (da) 2014-05-12
IL221091A0 (en) 2012-09-24
KR101893720B1 (ko) 2018-08-30
US9358309B2 (en) 2016-06-07
RU2560587C9 (ru) 2015-11-27
BR112012018843B8 (pt) 2020-12-22
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
PH12017501038B1 (en) 2019-02-22
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
EP2705857B1 (en) 2016-06-22
EP2528627B1 (en) 2014-03-19
PH12017501038A1 (en) 2017-12-11
RS53346B (sr) 2014-10-31
EP2528627A2 (en) 2012-12-05
US20120301396A1 (en) 2012-11-29
BR112012018843A8 (pt) 2017-12-19
RU2012135430A (ru) 2014-03-10
CA2786655C (en) 2016-12-13
ES2469140T3 (es) 2014-06-17
DK2705857T3 (en) 2016-08-29
AU2011209441A1 (en) 2012-07-19
KR101758409B1 (ko) 2017-07-14
JP2015057415A (ja) 2015-03-26
HRP20140538T1 (hr) 2014-07-18
SI2528627T1 (sl) 2014-08-29
CN104338154A (zh) 2015-02-11
US8628749B2 (en) 2014-01-14
JP5855209B2 (ja) 2016-02-09
ZA201205007B (en) 2013-09-25
IL237507A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
ES2592402T3 (es) Radioinmunoconjugados y usos de los mismos
ES2364811T3 (es) Conjugados de unión con un re.
US10646599B2 (en) Method for upregulating antigen expression
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
Fani et al. 177Lu-labeled-VG76e monoclonal antibody in tumor angiogenesis: A comparative study using DOTA and DTPA chelating systems
HK1195736B (en) Radioimmunoconjugates and their use
WO2025247428A1 (zh) 一种双功能性融合蛋白、放射性核素标记物及其应用
CN120550152A (zh) 包含抗b7-h3抗体的免疫缀合物及其应用
HK1179157B (en) Radioimmunoconjugates and uses thereof
Vera et al. 177Lu/90Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation